FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912202910> ?p ?o ?g. }

• W2912202910 endingPage "985" @default.
• W2912202910 startingPage "974" @default.
• W2912202910 abstract "Epidermal growth factor receptor (EGFR) is a transmembrane cell surface receptor that is frequently overexpressed and/or mutated in many cancers. Therapies targeting EGFR have poor outcomes due to the lack of reliable diagnostic tests to monitor EGFR. Current in vitro EGFR diagnostic methods are invasive, requiring biopsies, which limits tumor sampling and availability. EGFR molecular imaging provides non-invasive whole-body images capable of detecting primary tumors and metastases, which can be used to diagnose and monitor response to therapy. Methods: We evaluated properties of two anti-EGFR fragments, 8708 and 8709, as molecular-targeted imaging probes. 8708 and 8709 are anti-EGFR antigen binding fragments (Fabs) that recognize domain I/II of EGFR, which is distinct from epitopes recognized by current anti-EGFR therapeutic antibodies. We used complementarity determining region sequences from 8708 and 8709 Fabs to generate an anti-EGFR IgG and (scFv)2 and scFv-Fc antibody fragments. We expressed, purified, and labeled the IgG and fragments with IRDye800CW and used them to image EGFR-positive and -negative xenografts in CD-1 nude mice. 8709 scFv-Fc was also tested for competitive binding with the therapeutic anti-EGFR antibody nimotuzumab and for quantifying ratios of EGFR and EGFRvIII deletion mutant. Results: IRDye800CW-labeled 8708 (scFv)2 and 8709 scFv-Fc imaging probes showed high levels of accumulation and good retention in EGFR-positive xenografts, with peak accumulation occurring at 24 and 48 hours post injection, respectively. IRDye680RD-labeled 8709 scFv-Fc did not compete with IRDye800CW-labeled nimotuzumab for EGFR binding as assayed by flow cytometry using an EGFR-positive cell line. IRDye680RD-labeled 8709 scFv-Fc and IRDye800CW-labeled nimotuzumab used in combination were able to determine the ratio of cells expressing EGFR and a deletion mutant EGFRvIII. Conclusion: IRDye800CW-labeled 8708 (scFv)2 and 8709 scFv-Fc had desirable binding affinities, clearance times, and tumor accumulation to be used for imaging in combination with current EGFR targeted therapies. This study highlights the potential for using 8708 (scFv)2 and 8709 scFv-Fc as EGFR diagnostic and therapy monitoring tools." @default.
• W2912202910 created "2019-02-21" @default.
• W2912202910 creator A5034431480 @default.
• W2912202910 creator A5074593945 @default.
• W2912202910 creator A5076963479 @default.
• W2912202910 creator A5078704965 @default.
• W2912202910 creator A5078805938 @default.
• W2912202910 creator A5079203897 @default.
• W2912202910 date "2019-01-01" @default.
• W2912202910 modified "2023-10-16" @default.
• W2912202910 title "Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments" @default.
• W2912202910 cites W1583421095 @default.
• W2912202910 cites W1921134595 @default.
• W2912202910 cites W1931270562 @default.
• W2912202910 cites W1965580949 @default.
• W2912202910 cites W1973071934 @default.
• W2912202910 cites W1984227078 @default.
• W2912202910 cites W2006168411 @default.
• W2912202910 cites W2007370292 @default.
• W2912202910 cites W2037690883 @default.
• W2912202910 cites W2077513301 @default.
• W2912202910 cites W2092692114 @default.
• W2912202910 cites W2094962167 @default.
• W2912202910 cites W2101904470 @default.
• W2912202910 cites W2101979288 @default.
• W2912202910 cites W2108329606 @default.
• W2912202910 cites W2149053783 @default.
• W2912202910 cites W2566896698 @default.
• W2912202910 cites W2604499807 @default.
• W2912202910 cites W2763302201 @default.
• W2912202910 cites W2780183249 @default.
• W2912202910 cites W2792045095 @default.
• W2912202910 cites W2810142842 @default.
• W2912202910 cites W2891465557 @default.
• W2912202910 cites W2893956305 @default.
• W2912202910 doi "https://doi.org/10.7150/thno.30835" @default.
• W2912202910 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6401412" @default.
• W2912202910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30867810" @default.
• W2912202910 hasPublicationYear "2019" @default.
• W2912202910 type Work @default.
• W2912202910 sameAs 2912202910 @default.
• W2912202910 citedByCount "9" @default.
• W2912202910 countsByYear W29122029102020 @default.
• W2912202910 countsByYear W29122029102021 @default.
• W2912202910 countsByYear W29122029102022 @default.
• W2912202910 countsByYear W29122029102023 @default.
• W2912202910 crossrefType "journal-article" @default.
• W2912202910 hasAuthorship W2912202910A5034431480 @default.
• W2912202910 hasAuthorship W2912202910A5074593945 @default.
• W2912202910 hasAuthorship W2912202910A5076963479 @default.
• W2912202910 hasAuthorship W2912202910A5078704965 @default.
• W2912202910 hasAuthorship W2912202910A5078805938 @default.
• W2912202910 hasAuthorship W2912202910A5079203897 @default.
• W2912202910 hasBestOaLocation W29122029101 @default.
• W2912202910 hasConcept C147483822 @default.
• W2912202910 hasConcept C153911025 @default.
• W2912202910 hasConcept C159654299 @default.
• W2912202910 hasConcept C170493617 @default.
• W2912202910 hasConcept C185592680 @default.
• W2912202910 hasConcept C195616568 @default.
• W2912202910 hasConcept C203014093 @default.
• W2912202910 hasConcept C2776055544 @default.
• W2912202910 hasConcept C2776362946 @default.
• W2912202910 hasConcept C2779438470 @default.
• W2912202910 hasConcept C502942594 @default.
• W2912202910 hasConcept C542903549 @default.
• W2912202910 hasConcept C55493867 @default.
• W2912202910 hasConcept C86803240 @default.
• W2912202910 hasConceptScore W2912202910C147483822 @default.
• W2912202910 hasConceptScore W2912202910C153911025 @default.
• W2912202910 hasConceptScore W2912202910C159654299 @default.
• W2912202910 hasConceptScore W2912202910C170493617 @default.
• W2912202910 hasConceptScore W2912202910C185592680 @default.
• W2912202910 hasConceptScore W2912202910C195616568 @default.
• W2912202910 hasConceptScore W2912202910C203014093 @default.
• W2912202910 hasConceptScore W2912202910C2776055544 @default.
• W2912202910 hasConceptScore W2912202910C2776362946 @default.
• W2912202910 hasConceptScore W2912202910C2779438470 @default.
• W2912202910 hasConceptScore W2912202910C502942594 @default.
• W2912202910 hasConceptScore W2912202910C542903549 @default.
• W2912202910 hasConceptScore W2912202910C55493867 @default.
• W2912202910 hasConceptScore W2912202910C86803240 @default.
• W2912202910 hasIssue "4" @default.
• W2912202910 hasLocation W29122029101 @default.
• W2912202910 hasLocation W29122029102 @default.
• W2912202910 hasLocation W29122029103 @default.
• W2912202910 hasLocation W29122029104 @default.
• W2912202910 hasOpenAccess W2912202910 @default.
• W2912202910 hasPrimaryLocation W29122029101 @default.
• W2912202910 hasRelatedWork W146556653 @default.
• W2912202910 hasRelatedWork W2038315376 @default.
• W2912202910 hasRelatedWork W2056231397 @default.
• W2912202910 hasRelatedWork W2060875961 @default.
• W2912202910 hasRelatedWork W2095707082 @default.
• W2912202910 hasRelatedWork W2894706921 @default.
• W2912202910 hasRelatedWork W2912202910 @default.
• W2912202910 hasRelatedWork W3029316243 @default.
• W2912202910 hasRelatedWork W3124478254 @default.

• next